Biocon Results

Revenue driven by gains from US Oncology and Insulins franchises

Biocon Q4FY24 results: The company board has recommended a final dividend at the rate of 10 per cent i.e. Re. 0.50 per equity share

About a week ago, Syngene International's share price declined by 3 per cent following UBS Global Research stock downgrade to sell

On a sequential basis, the company exhibited a 1.15 per cent increase in revenue along with PAT, which rose 23.8 per cent

Biotechnology major Biocon on Friday said its consolidated net profit rose an over two-fold to Rs 173 crore for the second quarter ended September 30, 2023. The company had reported a net profit of Rs 82 crore for the July-September period of the last fiscal. Total income rose to Rs 3,620 crore for the second quarter as against Rs 2,384 crore in the year-ago period, Biocon Ltd said in a regulatory filing. Shares of the company on Friday ended 0.11 per cent higher at Rs 227.35 apiece on the BSE.

Yesafili aims to treat various visual impairments and age-related macular degeneration

For the entire financial year, the company's net profit saw a decline of 29 per cent to Rs 462.7 crore, as compared to Rs 648.4 crore in 2021-22

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

The Bengaluru-headquartered company posted 10 per cent growth in consolidated revenue on a y-o-y basis to Rs 1,760 crore in Q2

Analysts estimate 38 per cent annual growth in earnings during FY20-22

The stock however pared some gains and settled at Rs 513.55, up 15 per cent on BSE